Gritstone Oncology, Inc. Gains 248.51%
Tue, Jan 19, 2021 at 05:30 PM
Gritstone Oncology, Inc. (GRTS:NASDAQ) rocketted at $22.27, a gain of 248.5%. On Fri 15 Jan 21, GRTS:NASDAQ touched a New 2-Week High of $6.39. The stock got featured on our News Catalysts scanner on Tue 19 Jan 21 at 04:26 PM in the 'BIOTECH' category. From Mon 04 Jan 21, the stock recorded 77.78% Up Days and 80.00% Green Days
About Gritstone Oncology, Inc. (GRTS:NASDAQ)
Gritstone Oncology Inc is a United States based immune-oncology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors including GRANITE-001 and SLATE-001.
Top 10 Gainers:
- Gritstone Oncology, Inc. (GRTS:NASDAQ), 248.51%
- Aclaris Therapeutics, Inc. (ACRS:NASDAQ), 220.24%
- Inuvo, Inc. (INUV:NYSEMKT), 123.01%
- Senseonics Holdings, Inc. (SENS:NYSEMKT), 80.38%
- Gevo, Inc. (GEVO:NASDAQ), 72.34%
- TransEnterix, Inc. (TRXC:NYSEMKT), 68.6%
- ENDRA Life Sciences Inc. (NDRA:NASDAQ), 65.71%
- Dare Bioscience, Inc. (DARE:NASDAQ), 63.89%
- Motus GI Holdings, Inc. (MOTS:NASDAQ), 54.87%
- EHang Holdings Limited (EH:NASDAQ), 53.48%